NCT02564263View on ClinicalTrials.gov

Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)

PHASE3CompletedINTERVENTIONAL

Enrollment

628

Participants

Timeline

Start Date

December 1, 2015

Primary Completion Date

October 15, 2018

Study Completion Date

March 14, 2022

Conditions

Esophageal CarcinomaEsophagogastric Junction Carcinoma

Interventions

BIOLOGICAL

pembrolizumab

200 mg administered as IV infusion on Day 1 of every 21-day cycle

DRUG

paclitaxel

80-100 mg/m\^2 administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle

DRUG

docetaxel

75 mg/m\^2 administered as IV infusion on Day 1 of every 21-day cycle

DRUG

irinotecan

180 mg/m\^2 administered as IV infusion on Day 1 of every 14-day cycle

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02564263 - Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181) | Biotech Hunter | Biotech Hunter